FDA Is Moving Faster on CRISPR Trials. Insurance Coverage Is Not Keeping Up.
FDA Is Moving Faster on CRISPR Trials. Insurance Coverage Is Not Keeping Up.
Abstract: The FDA under the current administration has streamlined Investigational New Drug (IND) application requirements for CRISPR and gene editing clinical trials targeting rare diseases, reducing certain documentation burdens and shortening review timelines to accelerate trial launch. While this bipartisan regulatory shift genuinely expands earlier access for rare disease patients, it does not resolve the most persistent barrier most patients will face: even after a therapy earns full FDA approval, private insurers and state Medicaid programs routinely deny coverage for years by classifying it as experimental. CAR-T cell therapy traveled exactly this road before CMS coverage normalized, and the first CRISPR therapies already approved for sickle cell disease are following the same pattern.
What Just Happened
The FDA has moved to reduce the regulatory burden on Investigational New Drug applications for clinical trials testing CRISPR and other gene editing technologies in patients with rare diseases. Under the streamlined framework, sponsors pursuing IND approval for rare disease gene editing trials may face reduced chemistry, manufacturing, and controls (CMC) documentation requirements at the early trial stages, expedited pre-IND meeting processes, and more flexible early-phase safety data standards, particularly for conditions with no existing approved therapy.1
The rationale is straightforward: for a patient with a rare disease that has no approved treatment, the risk calculus of early-stage trial participation is different than for a patient who has existing alternatives. The FDA's Rare Disease Innovation Hub and the Office of Orphan Products Development have both signaled that the current approach reflects a policy priority to accelerate rare disease pipeline development.2
Notably, this initiative has drawn support from across the political spectrum. Advocates who have long argued that FDA requirements were slowing potentially curative therapies to patients with no other options are aligned with the current administration's stated deregulatory goals. The result is one of the few areas in current health policy where RFK Jr.'s stated skepticism of regulatory overreach and mainstream rare disease scientists' frustration with timeline-to-patient gaps point in the same direction.3
What the Evidence Shows
The CRISPR Therapy Landscape in 2026
The field reached a milestone in December 2023 when the FDA approved the first two CRISPR-based therapies for human use — both targeting hemoglobin disorders.
Casgevy (exagamglogene autotemcel, or exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, received FDA approval for sickle cell disease with recurrent vaso-occlusive crises and for transfusion-dependent beta-thalassemia, in patients 12 years and older.4 Casgevy works by editing the patient's own stem cells to reactivate fetal hemoglobin production, which compensates for the defective adult hemoglobin. In pivotal trial data published in the New England Journal of Medicine, 93.5% of evaluable patients with sickle cell disease achieved freedom from vaso-occlusive crises for at least 12 consecutive months after a single Casgevy treatment.5
Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio using lentiviral rather than CRISPR-based gene editing, also received FDA approval in December 2023 for sickle cell disease in patients 12 and older.4
Casgevy's list price at launch was approximately $2.2 million per treatment course — a figure that immediately became a focal point in debates about access.6 This price reflects the one-time curative intent of the therapy (a single treatment that may eliminate lifelong disease burden) but also creates an immediate access problem for payers who are accustomed to structuring reimbursement around ongoing drug costs rather than single large payments.
The Pipeline Behind These Approvals
The streamlined IND pathway creates a shorter runway from laboratory to first-in-human trial for therapies targeting conditions like Duchenne muscular dystrophy, Huntington's disease, hereditary transthyretin amyloidosis, and rare metabolic disorders. The American Society of Gene and Cell Therapy has tracked more than 1,000 gene therapy programs in development globally as of recent years, with a significant number targeting rare monogenic diseases where a single genetic correction could be curative.7
The Insurance Reality
FDA Approval Is Not Coverage Approval
The first lesson from Casgevy and Lyfgenia is that FDA approval and insurance coverage are entirely separate processes. Both therapies were approved in December 2023. Two years later, coverage remains inconsistent and frequently contested.
Private insurers have applied a range of coverage-limiting strategies. Some plans classified both therapies as investigational or experimental for months after approval, citing the limited long-term data available from clinical trials. Others restricted coverage to specific academic medical center treatment sites, limiting geographic access. Still others built in prior authorization requirements so burdensome that relatively few patients had successfully navigated the process in the first year after approval.6
Medicaid coverage, which matters enormously because sickle cell disease disproportionately affects Black Americans and many are covered under state Medicaid programs, varies substantially by state. Some states moved quickly to add Casgevy to their Medicaid formularies. Others did not, citing budget impact concerns about a $2.2 million per-patient cost in a fee-for-service model.
CAR-T Therapy Wrote the Playbook
This pattern is not new. The same cycle played out with CAR-T cell therapies after the first CAR-T products received FDA approval in 2017.8
Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) were FDA-approved in August and October 2017, respectively, for B-cell malignancies. Both represented genuinely transformative therapies, with remission rates in heavily pretreated patients that had never before been achieved. Both were also denied by commercial insurers as experimental or investigational for extended periods after approval.
CMS issued a National Coverage Determination for CAR-T cell therapy in 2019, two years after the first approval — establishing that Medicare would cover FDA-approved CAR-T therapies when administered at specific qualified treatment facilities.8 Commercial coverage normalization followed, slowly, over subsequent years. The patients who needed these therapies between 2017 and 2019 faced a coverage gap during the critical period when the science said a treatment existed and the insurance system said it did not.
CRISPR therapies are following this same arc, and the FDA's streamlined trial pathway will produce more approved therapies faster — meaning the insurance gap problem is going to expand before it contracts.
The Experimental Classification Problem
Insurers use the language of "experimental" or "investigational" as a coverage exclusion tool. The clinical and legal definition of experimental depends on whether a therapy has received FDA approval for the relevant indication and whether it meets the generally accepted medical standards of the relevant specialty society. Both Casgevy and Lyfgenia clear this bar — they are FDA-approved, and major hematology societies have issued guidance supporting their use.9
However, plan language is often written broadly enough to allow insurers to classify a therapy as experimental if they contend there is insufficient long-term evidence, if the plan's medical policy was not updated after approval, or if the therapy is listed under a blanket gene therapy exclusion in an older plan document. These are challengeable positions — but challenging them requires documentation, appeals, and in some cases external review.
What This Means for You
If you or someone you care for has a rare disease and you are watching the CRISPR pipeline, the FDA streamlining news is genuinely good. It means trials you might qualify for could open sooner. It means therapies that might help you could reach approval faster.
But it does not mean coverage will follow automatically. If anything, faster approvals mean more patients will be caught in the gap between an FDA-approved product and an insurance system that has not yet decided whether to pay for it.
Understanding the difference between trial access and commercial access is the most important thing you can do right now.
What You Can Do
1. Know the difference between a clinical trial and a commercial prescription. If you are eligible for a CRISPR or gene therapy trial, the trial itself is typically sponsored and funded by the pharmaceutical company or academic institution running it. You receive the therapy as a trial participant, often at no cost to you. This is entirely separate from the commercial approval and insurance coverage process that follows if the therapy is eventually approved.
2. Search ClinicalTrials.gov for open trials matching your diagnosis. The National Institutes of Health maintains a registry of all registered U.S. clinical trials at clinicaltrials.gov. Search your diagnosis plus "CRISPR" or "gene therapy" and filter for actively recruiting trials. Each listing includes contact information for the trial site.
3. If you are seeking a commercially approved gene therapy (like Casgevy for sickle cell disease), request your insurer's written coverage policy before your physician submits any orders. Coverage policies for gene therapies are often separate documents from standard formulary lists, and they may contain specific criteria around treatment site, patient eligibility, or required pre-authorization documentation.
4. If you receive a denial citing "experimental" or "investigational," request the specific medical policy language your insurer used. Under the terms of your plan and most state insurance regulations, you are entitled to see the specific policy criteria that were applied to your claim. An appeal challenging an experimental classification for an FDA-approved therapy is a strong appeal, particularly when you can cite FDA approval documentation and relevant specialty society guidelines.
5. Connect with your disease's patient advocacy organization before navigating the insurance process. Organizations like the Sickle Cell Disease Association of America, NORD, and disease-specific foundations often track coverage patterns across insurers and can direct you to resources, patient navigators, and legal aid organizations that have successfully appealed similar denials.
Ellen can help you build your appeal. Start here
Frequently Asked Questions
If a CRISPR therapy is FDA-approved, can my insurer really deny it as experimental?
Yes, and it happens frequently. FDA approval establishes that a therapy is safe and effective enough to be sold in the United States. It does not compel any insurer to cover it. Commercial payers make separate coverage decisions based on their own medical policies, which are updated on their own timelines. Denials citing "experimental" or "investigational" language for FDA-approved therapies are common but are also often successfully reversed on appeal, particularly when supported by physician documentation and specialty society guidance.
How is a clinical trial different from getting the treatment through insurance?
In a clinical trial, the therapy is provided by the trial sponsor as part of a research protocol. You do not go through your insurer to receive the treatment. The sponsor typically covers the cost of the investigational drug and related study procedures. After a therapy is approved and available commercially, access then runs through the standard insurance prior authorization and coverage process. Some patients gain access during trials who would later struggle to access the same therapy commercially.
Why does a therapy that costs $2.2 million get approved but not covered?
FDA approval and insurance coverage are governed by entirely separate legal frameworks. The FDA evaluates safety and efficacy. Insurance coverage is a contract between you, your employer or plan sponsor, and the insurance company, governed by state insurance law and federal law for certain plan types. Insurers make coverage decisions based on their interpretation of medical necessity, their formularies, and their medical policies. Price alone is not a legal basis for denial, but price affects formulary placement, prior authorization stringency, and the speed at which plans process coverage decisions for new therapies.